<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038727</url>
  </required_header>
  <id_info>
    <org_study_id>IND - DK048489</org_study_id>
    <secondary_id>U01DK048489</secondary_id>
    <nct_id>NCT00038727</nct_id>
    <nct_alias>NCT00353314</nct_alias>
  </id_info>
  <brief_title>Diabetes Prevention Program Outcomes Study</brief_title>
  <acronym>DPPOS</acronym>
  <official_title>Diabetes Prevention Program Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indian Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Clinical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an
      intensive lifestyle or metformin to prevent or delay the development of diabetes in a high
      risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended
      early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced
      diabetes onset by 31%.

      DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable
      DPP participants. This group of participants is nearly 50% minority and represents the
      largest IFG/IGT population ever studied. Clinically important research questions remain that
      focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course
      of precisely known new onset diabetes, in particular regarding microvascular disease, CVD
      risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in
      minority populations.

      The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of
      the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and
      high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend
      annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on
      cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and
      import.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current DPPOS Executive Summary and protocol, as well as DPPOS protocol and lifestyle
      manuals and publications are available at: https://dppos.bsc.gwu.edu/web/dppos/dppos
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label phase for metformin</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Diabetes.</measure>
    <time_frame>2008</time_frame>
    <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram OGTT, and confirmed with a repeat test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Aggregate Microvascular Complication</measure>
    <time_frame>2012-2013</time_frame>
    <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on eGFR by CKD-Epi (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cancer Except Non-melanoma Skin Cancer</measure>
    <time_frame>1996-2021</time_frame>
    <description>All primary incident cancers except non-melanoma skin cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>1996-2025</time_frame>
    <description>Defined as MI, stroke and CVD death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular and Cardiovascular Disease Risk Factors</measure>
    <time_frame>2021</time_frame>
    <description>Blood pressure, lipids, medication use, weight, insulin resistance, HbA1c, physical activity by MAQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging Related Outcomes - Cognitive and Physical Function</measure>
    <time_frame>2010 and 2012</time_frame>
    <description>Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ). Physical function assessed with the same two well-validated composite measures : the Short Physical Performance Battery (SPPB) and the Cardiovascular Health Study Frailty criteria. The SPPB is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands. Frailty is classified based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subclinical Atherosclerosis</measure>
    <time_frame>2012</time_frame>
    <description>Measured using coronary artery calcification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Economic Analyses</measure>
    <time_frame>2002-2013</time_frame>
    <description>Quality of life measurements include Beck, SF-36, and QWB.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2779</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Cancer</condition>
  <condition>CVD</condition>
  <arm_group>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Original Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPPOS Group Lifestyle</intervention_name>
    <description>Quarterly group lifestyle sessions</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_label>3 Original Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered as 850mg twice per day, masked in DPP and open label in DPPOS</description>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPPOS Boost Lifestyle</intervention_name>
    <description>In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive Lifestyle Group Session</intervention_name>
    <description>16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_label>3 Original Placebo</arm_group_label>
    <other_name>ILS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participation as a volunteer in the DPP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Nathan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marinella Temprosa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Linder, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kishore Gadde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ehrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Furlong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefferson Medical College of Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Larsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald B Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen P Hazuda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Dabelea, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward S Horton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kahn, MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Dagogo-Jack, MD, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Molitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Barrett-Conner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Xavier Pi-Sunyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Marrero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanita Aroda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karol E Watson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherita Hill Golden, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Schade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Venditti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjerie Mau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Knowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SW Indian Center, NIDDK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santica M Marcovina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK Project Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dppos.org</url>
    <description>Study website</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00004992</url>
    <description>Clinical trials.gov entry for DPP</description>
  </link>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <results_reference>
    <citation>Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.</citation>
    <PMID>19878986</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75. doi: 10.1016/S2213-8587(15)00291-0. Epub 2015 Sep 13.</citation>
    <PMID>26377054</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2002</study_first_submitted>
  <study_first_submitted_qc>June 4, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2002</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>September 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2017</results_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DPP</keyword>
  <keyword>IGT</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Macrovascular disease</keyword>
  <keyword>Microvascular disease</keyword>
  <keyword>Lifestyle</keyword>
  <keyword>Metformin</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIDDK Repository</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All surviving DPP participants with consent were invited to enroll into DPPOS throughout the follow-up period. The majority of DPPOS participants were enrolled in 2002-2003.</recruitment_details>
      <pre_assignment_details>DPPOS covers 3 funding phases for the 3 study phases: DPPOS-1 (2002-2008), DPPOS-2 (2009-2014), DPPOS-3 (2015-2021). The groups are defined using the original randomized groups from DPP with recruitment period of 1996-1998.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Original Lifestyle</title>
          <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
        </group>
        <group group_id="P2">
          <title>2 Original Metformin</title>
          <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
        </group>
        <group group_id="P3">
          <title>3 Original Placebo</title>
          <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="916">Includes all enrollees from DPPOS 1-3</participants>
                <participants group_id="P2" count="927">Includes all enrollees from DPPOS 1-3</participants>
                <participants group_id="P3" count="936">Includes all enrollees from DPPOS 1-3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 1 Primary</title>
              <participants_list>
                <participants group_id="P1" count="910">As reported in the Lancet 2009</participants>
                <participants group_id="P2" count="924">As reported in the Lancet 2009</participants>
                <participants group_id="P3" count="932">As reported in the Lancet 2009</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 2 Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="915">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P2" count="926">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P3" count="935">As reported in Lancet Diabetes and Endocrinology 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 2 Primary</title>
              <participants_list>
                <participants group_id="P1" count="751">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P2" count="772">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P3" count="780">As reported in Lancet Diabetes and Endocrinology 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 3 Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="927"/>
                <participants group_id="P3" count="936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="927"/>
                <participants group_id="P3" count="936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Original Lifestyle</title>
          <description>randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
DPPOS Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B2">
          <title>2 Original Metformin</title>
          <description>randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day, masked in DPP and open label in DPPOS
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B3">
          <title>3 Original Placebo</title>
          <description>randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="916"/>
            <count group_id="B2" value="927"/>
            <count group_id="B3" value="936"/>
            <count group_id="B4" value="2779"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>An additional 3 participants were enrolled after publication</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="915"/>
                    <count group_id="B2" value="926"/>
                    <count group_id="B3" value="935"/>
                    <count group_id="B4" value="2776"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="54" spread="10"/>
                    <measurement group_id="B4" value="54" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="11.1"/>
                    <measurement group_id="B2" value="51.3" spread="10.1"/>
                    <measurement group_id="B3" value="50.7" spread="10.0"/>
                    <measurement group_id="B4" value="51.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="624"/>
                    <measurement group_id="B2" value="620"/>
                    <measurement group_id="B3" value="645"/>
                    <measurement group_id="B4" value="1889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="544"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="596"/>
                    <measurement group_id="B2" value="628"/>
                    <measurement group_id="B3" value="612"/>
                    <measurement group_id="B4" value="1836"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                    <measurement group_id="B2" value="927"/>
                    <measurement group_id="B3" value="936"/>
                    <measurement group_id="B4" value="2779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="6.5"/>
                    <measurement group_id="B2" value="33.8" spread="6.5"/>
                    <measurement group_id="B3" value="34.0" spread="6.5"/>
                    <measurement group_id="B4" value="33.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of Diabetes.</title>
        <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram OGTT, and confirmed with a repeat test).</description>
        <time_frame>2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Original Lifestyle</title>
            <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
          </group>
          <group group_id="O2">
            <title>2 Original Metformin</title>
            <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>3 Original Placebo</title>
            <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Diabetes.</title>
          <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram OGTT, and confirmed with a repeat test).</description>
          <units>diabetes incidence (cases per 100 person</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="927"/>
                <count group_id="O3" value="936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.8" upper_limit="5.8"/>
                    <measurement group_id="O2" value="6.4" lower_limit="5.9" upper_limit="7.1"/>
                    <measurement group_id="O3" value="7.8" lower_limit="7.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Aggregate Microvascular Complication</title>
        <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on eGFR by CKD-Epi (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
        <time_frame>2012-2013</time_frame>
        <population>Number with microvascular outcome data and included in the primary outcome analysis</population>
        <group_list>
          <group group_id="O1">
            <title>1 Original Lifestyle</title>
            <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
          </group>
          <group group_id="O2">
            <title>2 Original Metformin</title>
            <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>3 Original Placebo</title>
            <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Aggregate Microvascular Complication</title>
          <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on eGFR by CKD-Epi (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
          <population>Number with microvascular outcome data and included in the primary outcome analysis</population>
          <units>average percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="751"/>
                <count group_id="O2" value="772"/>
                <count group_id="O3" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.1" upper_limit="12.7"/>
                    <measurement group_id="O2" value="13" lower_limit="11.7" upper_limit="14.5"/>
                    <measurement group_id="O3" value="12.4" lower_limit="11.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cancer Except Non-melanoma Skin Cancer</title>
        <description>All primary incident cancers except non-melanoma skin cancer</description>
        <time_frame>1996-2021</time_frame>
        <posting_date>06/2021</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MACE</title>
        <description>Defined as MI, stroke and CVD death</description>
        <time_frame>1996-2025</time_frame>
        <posting_date>06/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microvascular and Cardiovascular Disease Risk Factors</title>
        <description>Blood pressure, lipids, medication use, weight, insulin resistance, HbA1c, physical activity by MAQ.</description>
        <time_frame>2021</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aging Related Outcomes - Cognitive and Physical Function</title>
        <description>Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ). Physical function assessed with the same two well-validated composite measures : the Short Physical Performance Battery (SPPB) and the Cardiovascular Health Study Frailty criteria. The SPPB is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands. Frailty is classified based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.</description>
        <time_frame>2010 and 2012</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subclinical Atherosclerosis</title>
        <description>Measured using coronary artery calcification.</description>
        <time_frame>2012</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life and Economic Analyses</title>
        <description>Quality of life measurements include Beck, SF-36, and QWB.</description>
        <time_frame>2002-2013</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until data lock of Jan 2014</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Original Lifestyle</title>
          <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
        </group>
        <group group_id="E2">
          <title>2 Original Metformin</title>
          <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
        </group>
        <group group_id="E3">
          <title>3 Original Placebo</title>
          <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Costart dictionary</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="927"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="936"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="472" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="482" subjects_at_risk="926"/>
                <counts group_id="E3" subjects_affected="492" subjects_at_risk="935"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any SAE Report</sub_title>
                <counts group_id="E1" events="1099" subjects_affected="472" subjects_at_risk="916"/>
                <counts group_id="E2" events="1122" subjects_affected="482" subjects_at_risk="926"/>
                <counts group_id="E3" events="1103" subjects_affected="492" subjects_at_risk="935"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Costart dictionary</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1000"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1000"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sprains and fractures requiring medical attention</sub_title>
                <counts group_id="E1" events="1000" subjects_affected="43" subjects_at_risk="1000"/>
                <counts group_id="E2" events="1000" subjects_affected="41" subjects_at_risk="1000"/>
                <counts group_id="E3" events="1000" subjects_affected="37" subjects_at_risk="1000"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marinella Temprosa, PI of Coordinating Center</name_or_title>
      <organization>George Washington University</organization>
      <phone>3018819260</phone>
      <email>ella@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

